3,4-diaminopyridine April 10, 2017 3,4-diaminopyridine Trade Name Orphan Indication Congenital myasthenic syndrome (CMS) USA Market Approval USA USA Designation Date 2017-03-30 00:00:00 Sponsor Jacobus Pharmaceutical Co., Inc.;37 Cleveland Lane;Princeton, New Jersey, 08540
